DDAVP TREATMENT OF CARDIOPULMONARY BYPASS-RELATED BLEEDING

DDAVP 治疗体外循环相关出血

• 批准号: 3863371
• 负责人: MARILYN J MANCO-JOHNSON
• 金额: --
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3863371
• 关键词: arginine vasopressin; blood disorder chemotherapy; cardiovascular disorder epidemiology; child (0-11); heart /lung bypass; hemorrhage; human subject; postoperative complications; von Willebrand factor; von Willebrand's disease

1: Role of DDAVP in the control of severe bleeding unresponsive to routine measures in the post-cardiopulmonary bypass (CPB) period; 2: Role of its prophylactic use in patients at risk for post-operative bleeding; 3: Etiology of this bleeding, specifically with regard to abnormalities in von Willebrand factor (vWF); and 4: Prevalence and natural history of coagulopathies associated with CHD.

1：DDAVP在控制常规治疗无效的严重出血中的作用 体外循环（CPB）后期间的措施; 2：其作用 在有术后出血风险的患者中预防性使用; 3： 这种出血的病因，特别是关于血管内皮细胞的异常， Willebrand因子（vWF）;和4： 与CHD相关的凝血功能障碍。